Autoantibodies associated with diseases of the CNS: new developments and future challenges.
about
Consequences of repeated blood-brain barrier disruption in football playersChannelopathiesAntibody-associated epilepsies: Clinical features, evidence for immunotherapies and future research questionsLimbic Encephalitis: Potential Impact of Adaptive Autoimmune Inflammation on Neuronal Circuits of the AmygdalaCD8(+) T Cell-Mediated Neuronal Dysfunction and Degeneration in Limbic EncephalitisUtility of Plasmapheresis in Autoimmune-Mediated Encephalopathy in Children: Potentials and ChallengesLGI proteins in the nervous system.Cell-surface central nervous system autoantibodies: clinical relevance and emerging paradigmsIon channels in genetic and acquired forms of epilepsy.Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous systemAutoimmune encephalitis in psychiatric institutions: current perspectivesNeuroinflammation: Ways in Which the Immune System Affects the BrainAntigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune DiseasesAntibody-Mediated Autoimmune Encephalopathies and ImmunotherapiesFaciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotypeFunctional, Structural, and Neurotoxicity Biomarkers in Integrative Assessment of Concussions.Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination.Molecular substrates of schizophrenia: homeostatic signaling to connectivitySubsequent brain tumors in patients with autoimmune diseaseImmunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitisPaediatric autoimmune encephalopathies: clinical features, laboratory investigations and outcomes in patients with or without antibodies to known central nervous system autoantigens.Rasmussen's encephalitis: clinical features, pathobiology, and treatment advances.Hughes syndrome and epilepsy: when to test for antiphospholipid antibodies?Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-D-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomographyBlood-brain barrier dysfunction and epilepsy: pathophysiologic role and therapeutic approachesCentral nervous system involvement in adults with epidemic hemolytic uremic syndrome.Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study.Hello from the Other Side: How Autoantibodies Circumvent the Blood-Brain Barrier in Autoimmune Encephalitis.Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitisClinical features of limbic encephalitis with LGI1 antibody.Is peripheral immunity regulated by blood-brain barrier permeability changes?Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?Limbic encephalitis: Clinical spectrum and long-term outcome from a developing country perspective.Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomesNK cells mediate the cumulative analgesic effect of electroacupuncture in a rat model of neuropathic pain.Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders.Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton.N-methyl-D-aspartate receptor antibodies in post-herpes simplex virus encephalitis neurological relapse.CMV-associated encephalitis and antineuronal autoantibodies--a case report
P2860
Q21133671-7C209D7F-5CA2-4459-BDA0-6362684DD245Q24601791-1EA6F5CD-A342-4938-9B81-D6F5D3EFF656Q26741919-D69CF640-B25D-4179-86FB-2F814B9DD144Q26797363-34C3FAF6-7EA6-4354-93C1-820F74F985C7Q26800028-01A862A2-E519-403C-8F5D-0BD100243DCBQ26865785-A19D4912-7595-4042-AF5D-D910C98E6B19Q26998200-820F8A4C-F60B-4E7F-8DD8-C9A348CD8EC2Q27006941-A84B5D83-4C6C-49CF-910E-C6A54DFF4A04Q27693827-00B4FC16-0DBF-414C-8716-1399A085C8C7Q28075974-50744BB6-11AE-4D91-B2CC-410C80394A8FQ28079666-C7FD8616-2D7A-418A-8C3D-CC21BC6099ACQ28080620-F9001B45-6C20-4D4B-8176-25D51D8AB29AQ28080791-0ABF724F-2DE7-4FD3-92EF-CAEEC51DF58EQ28084055-77220815-BFC6-4404-A5A6-DEB4D3FB5B3AQ28298099-86FF3738-ACCD-4B54-BE75-F4BD1EE552A1Q30372117-65E809B5-B43B-4DCB-9D15-EAC9D5ECD463Q30375856-45E149D8-9765-40E3-A528-EA306D2DA401Q30383611-DB68BFE1-242D-4B81-BF38-D123729372ACQ30432018-6B99056B-A057-45A7-B42C-A996997FD08EQ30519510-FA84D26E-F666-4A10-9AE3-B0766AE6CC2EQ30578301-E73D82E0-0E9A-4B04-8A6B-D1DD61704507Q30741122-BEF9A873-CEF3-42D9-9C30-DD4A473B09DAQ31101744-63165D1E-9742-47EF-AC9D-3E9DCD2F42B6Q31167257-43E91165-5CCC-4912-9277-DA4DCA5AECBAQ33354141-2A7CAA53-D9E9-4C6F-B996-995EB1F5A82DQ33405224-C35E9381-C0F6-4B16-8386-3E68AF4045B6Q33551430-DB7A1A8D-17A8-458C-9111-0984479FA751Q33586199-AEF504FB-F37B-457E-A85E-A75F97AF9320Q33603847-6895D906-4165-401F-9827-D53ABB89EC41Q33825874-6ADB69DA-01A4-4829-9DDB-A2925FA35C28Q33838466-4EEAF60A-F824-4538-A301-4832653E3DCFQ33871737-8ED05781-C2D4-4B0B-9855-9C1DFB1CB17DQ33877813-151C8C32-7B55-4C88-821D-B81187962C5AQ33937492-575DB829-40B3-432C-84F2-6F037202C572Q34123628-AFCD165D-48B8-4DBA-91FD-08323BB52979Q34306084-FC34ADCB-6633-41FF-883B-3C1E1CEE8B50Q34359264-24F0365A-ED80-4E42-90D5-64EAF4BF3862Q34368609-9F02FDA5-99A5-4B4F-9B97-1FC9AF27CEF1Q34369454-B54E9377-1421-494D-A001-9253ED6A0C9FQ34402966-2103CC0B-4239-4716-A81B-47B125F7E38C
P2860
Autoantibodies associated with diseases of the CNS: new developments and future challenges.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Autoantibodies associated with ...... opments and future challenges.
@en
Autoantibodies associated with ...... opments and future challenges.
@nl
type
label
Autoantibodies associated with ...... opments and future challenges.
@en
Autoantibodies associated with ...... opments and future challenges.
@nl
prefLabel
Autoantibodies associated with ...... opments and future challenges.
@en
Autoantibodies associated with ...... opments and future challenges.
@nl
P1433
P1476
Autoantibodies associated with ...... opments and future challenges.
@en
P2093
Christian G Bien
Patrick Waters
P304
P356
10.1016/S1474-4422(11)70096-5
P577
2011-08-01T00:00:00Z